The features of optimal nonhormonal therapy of vegetative disorders among women with postmenopause




postmenopause, vegetative disorders, phytotherapy, Cimicifuga racemosa, Vitae-Melatonin


Objectives: to evaluate the clinical effectiveness of the Vitae-Melatonin in the complex treatment of vegetative disorders in postmenopausal women.
Materials and methods. The 64 postmenopausal women who complained of vegetative disorders were included in our prospective study. Patients were divided into clinical groups. The first group consisted of 31 women who were prescribed a herbal preparation of Cimicifuga racemosa extract – 30 mg/day for 3 months. The second group included 33 patients who received in addition to the herbal medicine Vitae-Melatonin 3 mg/day every evening 2 hours before bedtime for 1 month. The clinical effectiveness of the therapy was assessed 1, 2 and 3 months after the start of treatment based on the dynamics of psychological disorders, somatic symptoms, vasomotor and sexual disorders, sleep problems and satisfaction with the therapy.
Results. The use of herbal medicine containing Cimicifuga rhizome extract alone or in combination with Vitae-Melatonin in postmenopausal women significantly reduced the manifestations of vegetative disorders, including psychological and dyssomnia in a month from the start of therapy. After 3 months from the start of therapy, the advantage of combined therapy involving Vitae-Melatonin compared to the monotherapy of Cimicifuga rhizome was marked by a significant reduction of psychological disorders, somatic symptoms, vasomotor disorders and sleep problems (р = 0.003, р = 0.01, р = 0.02 and p = 0.015, respectively). Patient satisfaction with the combined therapy of vegetative disorders during the menopause compared to monophytotherapy was probably higher (risk ratio 1.63, 95% confidence interval 1.09–2.44, p = 0.018). There was no significant difference between the two research groups regarding side effects during and after the use of the drugs (p > 0.05).
Conclusions. The use of Vitae-Melatonin at a dose of 3 mg/day in addition to phytotherapy in postmenopausal women had a clear clinical effect, which was a significant reduction of vegetative disorders, both compared to the initial indicators and in comparison with monophytotherapy. Results of the study showed the safety of melatonin, as well as the willingness of participants to continue using melatonin after 3 months of the treatment.

Author Biographies

D.H. Konkov, National Pirogov Memorial Medical University, Vinnytsia

MD, professor, Obstetrics and Gynecology Department No. 1

О.А. Taran, National Pirogov Memorial Medical University, Vinnytsia

MD, professor, Department of Obstetrics and Gynecology No. 1

V.O. Rud, National Pirogov Memorial Medical University, Vinnytsia

MD, professor, Department of Obstetrics and Gynecology No. 2

V.V. Klyvak, National Pirogov Memorial Medical University, Vinnytsia

PhD, associate professor, Obstetrics and Gynecology Department No. 2


  1. Adamczyk-Sowa, M., Sowa, P., Adamczyk, J., et al. “Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone.” J Physiol Pharmacol 67 (2016): 235–42.
  2. Bellipanni, G., Di Marzo, F., Blasi, F., Di Marzo, A. “Effects of melatonin in perimenopausal and menopausal women: our personal experience.” Ann N Y Acad Sci 1057 (2005): 393–402. DOI: 10.1196/annals.1356.030
  3. Berbets, A.M., Davydenko, I.S., Barbe, A.M., et al. “Melatonin 1A and 1B Receptors’ Expression Decreases in the Placenta of Women with Fetal Growth Restriction.” Reprod Sci 28.1 (2021): 197–206. DOI: 10.1007/s43032-020-00285-5
  4. Cardinali, D.P., Hardeland, R. “Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies.” Neuroendocrinology 104.4 (2017): 382–97. DOI: 10.1159/000446543
  5. Cheng, Y.S., Tseng, P.T., Wu, M.K., et al. “Pharmacologic and hormonal treatments for menopausal sleep disturbances: A network meta-analysis of 43 randomized controlled trials and 32,271 menopausal women.” Sleep Med Rev 57 (2021): 101469. DOI: 10.1016/j.smrv.2021.101469
  6. Chojnacki, C., Kaczka, A., Gasiorowska, A., et al. “The effect of long-term melatonin supplementation on psychosomatic disorders in postmenopausal women.” J Physiol Pharmacol 69.2 (2018). DOI: 10.26402/jpp.2018.2.15
  7. Cienfuegos, S., Gabel, K., Kalam, F., et al. “Changes in body weight and metabolic risk during time restricted feeding in premenopausal versus postmenopausal women.” Exp Gerontol 154 (2021): 111545. DOI: 10.1016/j.exger.2021.111545
  8. Dalton, D. “How evolutionary biology can explain why human and a few marine mammal females are the only ones that are menopausal.” J Theor Biol 21.543 (2022): 111123. DOI: 10.1016/j.jtbi.2022.111123
  9. de Villiers, T.J., Hall, J.E., Pinkerton, J.V., Pérez, S.C., et al. “Revised global consensus statement on menopausal hormone therapy.” Maturitas 91 (2016): 153–5. DOI: 10.1016/j.maturitas.2016.06.001
  10. Goyal, A., Terry, P.D., Superak, H.M., et al. “Melatonin supplementation to treat the metabolic syndrome: a randomized controlled trial.” Diabetol Metab Syndr 6 (2014): 124. DOI: 10.1186/1758-5996-6-124
  11. Greene, J.G. “Constructing a standard climacteric scale.” Maturitas 61.1–2 (2008): 78–84. DOI: 10.1016/j.maturitas.2008.09.011
  12. Hachul, H., Bittencourt, L.R., Soares, J.M. Jr, et al. “Sleep in post-menopausal women: differences between early and late post-menopause.” Eur J Obstet Gynecol Reprod Biol 145.1 (2009): 81–4. DOI: 10.1016/j.ejogrb.2009.03.019
  13. Hamoda, H., Panay, N., Pedder, H., et al. “The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women.” Post Reproductive Health 26.4 (2020): 181–209. DOI: 10.1177/2053369120957514
  14. Harpsøe, N.G., Andersen, L.P., Gögenur, I., Rosenberg, J. “Clinical pharmacokinetics of melatonin: a systematic review.” Eur J Clin Pharmacol 71.8 (2015): 901–9. DOI: 10.1007/s00228-015-1873-4
  15. Hickey, M., Szabo, R.A., Hunter, M.S. “Non-hormonal treatments for menopausal symptoms.” BMJ 359 (2017): j5101. DOI: 10.1136/bmj.j5101
  16. Inwald, E.C., Albring, C., Baum, E., et al. “Perimenopause and Postmenopause – Diagnosis and Interventions. Guideline of the DGGG and OEGGG (S3-Level, AWMF Registry Number 015-062, September 2020)”. Geburtshilfe Frauenheilkd 81.6 (2021): 612–36. DOI: 10.1055/a-1361-1948
  17. Baber, R.J., Panay, N., Fenton, A., IMS Writing Group. “2016 IMS Recommendations on women’s midlife health and menopause hormone therapy.” Climacteric 19.2 (2016): 109–50. DOI: 10.3109/13697137.2015.1129166. Available from: [https://www.].
  18. Johnson, A., Roberts, L., Elkins, G. “Complementary and alternative medicine for menopause.” J Evid Based Integr Med 24 (2019): 2515690X19829380.
  19. Kim, M.J., Yim, G., Park, H.Y. “Vasomotor and physical menopausal symptoms are associated with sleep quality.” PloS One 13.2 (2018): e0192934.
  20. Kim, M.R., Kim, H.J., Yu, S.H., et al. “Combination of red clover and hops extract improved menopause symptoms in an ovariectomized rat model.” Evid Based Complement Alternat Med 2020 (2020): 7941391. DOI: 10.1155/2020/7941391
  21. Kleemann, D.O., Kelly, J.M., Arney, L.J., et al. “Sexual behaviour, semen quality and fertility of young Border Leicester rams administered melatonin during spring.” Anim Reprod Sci 231 (2021): 106804. DOI: 10.1016/j.anireprosci.2021.106804
  22. Kuh, D., Cooper, R., Moore, A., et al. “Age at menopause and lifetime cognition: findings from a British birth cohort study.” Neurology 90.19 (2018): e1673-e1681. DOI: 10.1212/WNL.0000000000005486
  23. Laudisio, D., Barrea, L., Pugliese, G., et al. “A practical nutritional guide for the management of sleep disturbances in menopause.” Int J Food Sci Nutr 72.4 (2021): 432–46. DOI: 10.1080/09637486.2020.1851658
  24. Lundberg, G., Wu, P., Wenger, N. “Menopausal hormone therapy: a comprehensive review.” Curr Atheroscler Rep 22.8 (2020): 1–9. DOI: 10.1007/s11883-020-00854-8
  25. Mamontova, A.G., Usoltseva, E.N., Soloviev, A.G. “Algorithm for stratification of women for differentiated therapy of menopausal syndrome in combination with perimenopausal melatonin deficiency syndrome.” Adv Gerontol 33.6 (2020): 1137–41.
  26. Moroni, I., Garcia-Bennett, A., Chapman, J., et al. “Pharmacokinetics of exogenous melatonin in relation to formulation, and effects on sleep: a systematic review.” Sleep Med Rev 57 (2021): 101431. DOI: 10.1016/j.smrv.2021.101431
  27. Palacios, S., Stevenson, J.C., Schaudig, K., et al. “Hormone therapy for first-line management of menopausal symptoms: Practical recommendations.” Women’s Health 15 (2019): 1745506519864009. DOI: 10.1177/1745506519864009
  28. Parandavar, N., Abdali, K., Keshtgar, S., et al. “The effect of melatonin on sexual function among postmenopausal women: a randomized placebo controlled trial.” Nurs Midwifery Stud 6 (2017): 149–55. DOI: 10.4103/nms.nms_47_17
  29. Parandavar, N., Abdali, K., Keshtgar, S., et al. “The effect of melatonin on climacteric symptoms in menopausal women; a double-blind, randomized controlled, clinical trial.” Iran J Public Health 43.10 (2014): 1405–16.
  30. Proserpio, P., Marra, S., Campana, C., et al. “Insomnia and menopause: a narrative review on mechanisms and treatments.” Climacteric 23.6 (2020): 539–49. DOI: 10.1080/13697137.2020.1799973
  31. Rastmanesh, R., de Bruin, P.F. “Potential of melatonin for the treatment or prevention of obesity: an urgent need to include weight reduction as a secondary outcome in clinical trials of melatonin in obese patients with sleep disorders.” Contemp Clin Trials 33 (2012): 574–75. DOI: 10.1016/j.cct.2012.03.018
  32. Romo-Nava, F., Buijs, R.M., McElroy, S.L. “The use of melatonin to mitigate the adverse metabolic side effects of antipsychotics.” Handb Clin Neurol 179 (2021): 371–82. DOI: 10.1016/B978-0-12-819975-6.00024-8
  33. Toffol, E., Kalleinen, N., Haukka, J., et al. “Melatonin in perimenopausal and postmenopausal women: associations with mood, sleep, climacteric symptoms, and quality of life.” Menopause 21.5 (2014): 493–500. DOI: 10.1097/GME.0b013e3182a6c8f3
  34. Treister-Goltzman, Y., Peleg, R. “Melatonin and the health of menopausal women: a systematic review.” J Pineal Res 71.2 (2021): e12743. DOI: 10.1111/jpi.12743
  35. Vasconcelos-Raposo, J., Coelho, E., Fernandes, H.M., et al. “Factor structure and normative data of the Greene Climacteric Scale among postmenopausal Portuguese women.” Maturitas 72.3 (2012): 256–62. DOI: 10.1016/j.maturitas.2012.04.003
  36. Vijay, A., Kandula, N.R., Kanaya, A.M., et al. “Relation of menopause with cardiovascular risk factors in South Asian American women (from the MASALA Study).” Am J Cardiol 15.171 (2022): 165–70. DOI: 10.1016/j.amjcard.2022.01.063
  37. Vural, E.M., van Munster, B.C., de Rooij, S.E. “Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature.” Drugs Aging 31.6 (2014): 441–51. DOI: 10.1007/s40266-014-0178-0
  38. Walecka-Kapica, E., Klupińska, G., Chojnacki, J., et al. “The effect of melatonin supplementation on the quality of sleep and weight status in postmenopausal women.” Prz Menopauzalny 13.6 (2014): 334–8. DOI: 10.5114/pm.2014.47986
  39. Xie, Q.E., Wang, M.Y., Cao, Z.P., et al. “Melatonin protects against excessive autophagy-induced mitochondrial and ovarian reserve function deficiency though ERK signaling pathway in Chinese hamster ovary (CHO) cells.” Mitochondrion 61 (2021): 44–53. DOI: 10.1016/j.mito.2021.09.009
  40. Zetner, D., Andersen, L.P., Rosenberg, J. “Pharmacokinetics of alternative administration routes of melatonin: a systematic review.” Drug Res (Stuttg) 66.4 (2016): 169–73. DOI: 10.1055/s-0035-1565083
  41. Zhao, W., Smith, J.A., Bielak, L.F., et al. “Associations between polygenic risk score for age at menarche and menopause, reproductive timing, and serum hormone levels in multiple race/ethnic groups.” Menopause 28.7 (2021): 819–28. DOI: 10.1097/GME.0000000000001775
  42. Zisapel, N. “New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation.” Br J Pharmacol 175.16 (2018): 3190–9. DOI: 10.1111/bph.14116
  43. Zitňanová, I., Rakovan, M., Paduchová, Z., et al. “Oxidative stress in women with perimenopausal symptoms.” Menopause 18.11 (2011): 1249–55. DOI: 10.1097/gme.0b013e318224fa3d
  44. Burchynskyi, S.H. “Nootropic pharmacotherapy and its role in solving the problems of women health.” Int Neurolog J 2.80 (2016): 121–6. DOI: 10.22141/2224-0713.2.80.2016.74018
  45. Burchynskyi, S.H. “Pharmacotherapy of disorders of central nervous system function in gynecological practice as a problem of adaptation disorders correction.” Reproductive Endocrinology 2.28 (2016): 68–70. DOI: 10.18370/2309-4117.2016.28.52-55 Р



How to Cite

Konkov, D., Taran О., Rud, V., & Klyvak, V. . (2022). The features of optimal nonhormonal therapy of vegetative disorders among women with postmenopause. REPRODUCTIVE ENDOCRINOLOGY, (65), 90–96.



Management of menopause